Lawrence Sandra AJ sold $3K of SERA

Lawrence Sandra AJ sold 1,560 shares of SERA PROGNOSTICS, INC. (SERA) at $2.15 on 2026-06-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lawrence Sandra AJ
Published Jun 9, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SERA
Neutral
high confidence
Mentioned
$SERA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SERANeutralLow
01

Why it matters

This is a planned open-market sale by a director under a Rule 10b5-1 plan; such filings are generally low-signal for trading decisions unless they reveal a change in trading behavior or coincide with other material company news.

02

Market read

Low incremental information: a small, pre-arranged director sale with no accompanying fundamental catalyst in the text.

03

What to watch

10b5-1 plans can be executed regardless of company outlook; the disclosed sale size is small, so any inference about fundamentals is weak.

Relevance 2/10Novelty 2/10Timing: Filed 2026-06-09; sale executed 2026-06-08.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for SERA Progonostics, Inc.

Company-level read

Ticker impact

$SERANeutralHigh confidence
Context

SEC Form 4 shows director Lawrence Sandra AJ sold 1,560 SERA shares in an open-market transaction on 2026-06-08 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move driven solely by this Form 4 sale.

Evidence & confidence

The filing is an insider sale (not a buy), explicitly under a pre-arranged 10b5-1 plan, and the disclosed value (~$3.4K) is small relative to typical market-moving thresholds.

Market effects

None discernible from a small, planned director sale.

None.

None.

Counterpoint

If this director’s 10b5-1 sales are unusually frequent or accelerating, it could reflect private caution—though this single small sale is not enough to confirm that.

Key entities

  • SERA Progonostics, Inc.

    Company whose director insider sale is disclosed on SEC Form 4.

  • Lawrence Sandra AJ

    Director who sold 1,560 shares on 2026-06-08 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SERAMed

SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS Company Drives Significant Increases in Test Volume and Ordering Providers with Florida Becoming Second Medicaid State Covering Test • PreTRM® test volume increases 54% sequentially and approximately five-

$SERAMed

Sera (SERA) Q2 2026 Earnings Call Transcript

Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.

$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Sera Prognostics (Nasdaq: SERA) reported Q2 2026 revenue of $30,000 versus $17,000 in Q2 2025, with operating expenses of $10.0 million and a net loss of $9.1 million. The company said Illinois Medicaid coverage for PreTRM proteomic tests expanded, it launched a fourth payer partnership program, and PRIME trial data showed reduced NICU admissions in first-time mothers. Cash was about $80.3 million.

$SERAMed

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information t